Roivant gets FDA approval for LISRAYA brepocitinib in dermatomyositis
Roivant Sciences Ltd. said the FDA approved LISRAYA (brepocitinib) 30 mg for adult dermatomyositis following Phase 3 VALOR results showing clinical and functional gains.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.